Emergent BioSolutions to acquire anthrax treatment, move manufacturing to Baltimore

Standard

Emergent BioSolutions, a Gaithersburg-based drug maker with facilities in Baltimore, has acquired a drug used to treat anthrax from GlaxoSmithKline in a deal worth up to $96 million.

Under the deal announced Wednesday, Emergent will pay $76 million cash upfront and up to $20 million in product…

fromhttp://www.baltimoresun.com/business/bs-bz-emergent-acquisition-20170719-story.html

Advertisements